A Win For Alnylam In England As NICE Reverses Onpattro Rejection
Executive Summary
Health technology appraisal body NICE now says that Alnylam's innovative gene silencing drug is value for money for the treatment of the rare disease, hereditary transthyretin-related amyloidosis.